TGF-β (transforming growth factor-β) induces a cytostatic response in most normal cell types. In cancer cells, however, it often promotes metastasis, and its high expression is correlated with poor prognosis. In the present study, we show that S100A4, a metastasis-associated protein, also called metastatin-1, can physically and functionally interact with Smad3, an important mediator of TGF-β signalling. In agreement with its known property, S100A4 binds to Smad3 in a Ca 2+ -dependent manner. The S100A4-binding site is located in the N-terminal region of Smad3. S100A4 can potentiate transcriptional activity of Smad3 and the related Smad2. When exogenously expressed in MCF10CA1a.cl1, an MCF10-derived breast cancer cell line, S100A4 increases TGF-β-induced MMP-9 (matrix metalloproteinase-9) expression. On the other hand, depletion of S100A4 by siRNA (small interfering RNA) from the MDA-MB231 cell line results in attenuation of MMP-9 induction by TGF-β. Consistent with these observations, S100A4 increases cell invasion ability induced by TGF-β in MCF10CA1a.cl1 cells, and depletion of the protein in MDA-MB-231 cells inhibits it. Because expression of both S100A4 and TGF-β is highly elevated in many types of malignant tumours, S100A4 and Smad3 may cooperatively increase metastatic activity of some types of cancer cells.
INTRODUCTION
TGF-β (transforming growth factor-β) is a prototypical member of a multifunctional cytokine family that regulates a wide variety of cellular functions [1] . It signals through two types of transmembrane serine/threonine kinase receptors, TβRI and TβRII [2, 3] . On ligand binding, the two receptors form a complex, in which constitutively active TβRII phosphorylates and activates TβRI to phosphorylate Smad2 and 3, major intracellular effector proteins for TGF-β signalling. Phosphorylated Smad2/3 then form a complex with Smad4 and translocate into the nucleus. In the nucleus, Smad complexes interact with various factors to regulate gene expression [3] . Thus availability of different types of Smad-binding proteins in different cellular contexts can lead to diverse cell responses to the cytokine.
Growth inhibitory function is among the most important features of TGF-β, and it plays a central role in homoeostasis of normal cells. Accordingly, TGF-β is considered a tumour suppressor. The loss of a cytostatic response to TGF-β is indeed a hallmark of various kinds of cancer [4, 5] . Once cancer is established, however, the same cytokine paradoxically favours tumour progression and metastasis through increasing activities of invasion, mitogenesis and angiogenesis [1, 6] . Importantly, although genetic alterations of the TGF-β signalling components account for cancer development in some cases [5, 7] , this change of function often occurs with the main signalling components intact. This indicates that the same TGF-β signalling can result in opposite consequences in normal and cancer cells. Although what switches TGF-β from a tumour suppressor to a tumour promoter is not clear, it is obvious that TGF-β-mediated cell malignancy is regulated by multiple layers of molecular mechanisms [6, 8] .
Up-regulation of MMPs (matrix metalloproteinases) in cancer cells is a critical step for metastasis. MMPs promote cell invasion by degrading ECM (extracellular matrix) and regulating angiogenesis [9, 10] . Among the MMPs, MMP-2 and MMP-9 play major roles in cancer cell metastasis [9] . Importantly, their expression is regulated by TGF-β [9] . In cancer cells, other signalling pathways or factors are integrated in TGF-β signalling for MMP regulation. RTKs (receptor tyrosine kinases) have been reported to co-operate with TGF-β for inducing the oncogenic property of epithelial cells in mouse models [11] [12] [13] [14] . At the molecular level, EGF (epidermal growth factor) synergizes with TGF-β for induction of some MMPs [12, 13] . Moreover, a transcriptional co-activator, Cited {CBP [CREB (cAMP-response-element-binding protein)-binding protein]/p300-interacting transactivator with glutamic acid (E)/aspartic acid (D)-rich C-terminal domain} 2 has been shown to augment TGF-β-mediated up-regulation of MMP-9 and cell invasion in breast cancer cells [15] . This effect is through Smad2 and 3, indicating the pro-metastatic role of these transcription factors in cancer cells, and Cited2 provided an example that these Smads can increase their pro-metastatic activity through interaction with other cofactors. S100A4, also known as Mts-1 (metastatin-1), is a member of the S100 family calcium-binding proteins [16] . It is highly expressed in various metastatic tumour cells and its expression correlates with poor prognosis in different types of cancer [17] [18] [19] [20] . For this reason, it is recognized as a good molecular marker for clinical prognosis [21, 22] . Studies with mouse models have shown that S100A4 itself is not tumorigenic, but once a tumour is formed it enhances tumour invasiveness and metastasis [23, 24] . At the molecular level, some protein targets of S100A4 have been identified. These include a tumour suppressor, p53, and nonmuscle myosin. The binding of S100A4 on the C-terminal region of p53 interferes with its DNA-binding activity and transcriptional activity [25] . As a consequence, this interaction may indirectly contribute to the acquisition of an invasive phenotype [25, 26] . Binding of S100A4 to non-muscle myosin IIA stabilizes its monomeric state and destabilizes myosin filaments, leading to increased cell motility [27, 28] . The increased cell motility may contribute to metastasis. Thus, although the molecular mechanisms by which S100A4 induces a metastatic phenotype may not be fully understood, modulation of the function of its targets appears to be an important part of the role of S100A4.
In the present study, we have identified Smad3 as a new S100A4 target. Interaction of S100A4 with Smad3 augments TGF-β-mediated up-regulation of MMP-9, leading to an increase in cell invasion ability. The findings of the present study provide a new molecular mechanism for the regulation of metastatic ability by both TGF-β and S100A4.
EXPERIMENTAL

Constructs
Mammalian expression plasmids for 6 × Myc-Smad3, MycSmad2 and HA (haemagglutinin)-TβRI have been described previously [29] . pCMV5-3 × FLAG-p53 and c-Jun cDNA was kindly provided by Dr S. Hsu and Dr Y. Chen respectively [both at the NHRI (National Health Research Institutes, Taiwan)] The bacterial expression plasmid for the His-tag protein pET15b-S100A4 was a gift from Dr M. Takahashi (Division of Chemistry, Graduate School and Faculty of Science, Hokkaido University, Sapparo, Japan). pGEX4T-S100A4 was constructed by subcloning the S100A4 fragment from pET15b-S100A4. CS2-S100A4 was made by PCR-based subcloning. pGEX2T-Smad3 and 2, GAL4-Luc and GAL4-Smad3 were as described previously [29] . VP16-S100A4 and VP16-c-Jun were constructed by replacing the SgfI-PmeI barnase fragment with each cDNA in pFN10A (ACT) Flexi (Promega). pBABE-S100A4 was constructed by subcloning the S100A4 fragment into pBABE puro (Addgene).
Cell culture
MCF10CA1a.cl1 cells, a carcinoma cell line derived from the MCF10A breast epithelial cell line [30, 31] , were maintained in DMEM (Dulbecco's modified Eagle's medium)/F12 supplemented with 5 % horse serum and 1 % penicillin/streptomycin. HEK (human embryonic kidney)-293T cells were cultured in MEM (minimum essential medium), 10 % FBS (fetal bovine serum) and 1 % penicillin/streptomycin. Amphotrophic Phoenix cells (for retrovirus packaging) [32] and MDA-MB 231 were maintained in DMEM containing 10 % FBS and 1 % penicillin/streptomycin. Lipofectamine TM (Invitrogen) was used for transfection following the manufacturer's instructions.
Retroviral infection using Phoenix cells has been described previously [29] . MCF10CA1a.cl1 cells transduced with pBABE vector or pBABE-S100A4 were selected with 5 μg/ml puromycin.
siRNA (small interfering RNA) for S100A4 was purchased from Invitrogen. MDA-MB 231 cells were transfected with siRNA using Lipofectamine TM RNAi Max (Invitrogen) for 48 h.
GST (glutathione transferase) pulldown assay and co-immunoprecipitation
GST proteins were expressed in bacterial BL21(DE3) cells. Protein on the GST-Sepharose beads was quantified and adjusted so that an equal amount of protein was on the beads ( Figure 1A , right-hand panel). HEK-293T cells were transfected with Myc-Smad3, MycSmad2 or FLAG-p53, and were treated or untreated with 500 pM TGF-β (Peprotech) for 1 h. Cell lysate was prepared in TNTE buffer [10 mM Tris/HCl (pH 7.8), 150 mM NaCl and 1 % Nonidet P40], 10 mM sodium pyrophosphate, 25 mM NaF, 10 mM β-glycerophosphate, 1 mM DTT (dithiothreitol), 5 μg/ml RNase A and 1 × Complete protease inhibitor cocktail (Roche). GST or GST-S100A4 beads were incubated with 300 μg of lysate for 2 h in the presence of either 1 mM EGTA or CaCl 2 . Beads were washed with the same buffer. Proteins remaining on the beads were visualized by Western blot analysis with an anti-Myc or anti-FLAG antibody (Sigma).
For co-immunoprecipitation of endogenous Smad3 and S100A4, MDA-MB-231 cells were treated and lysed as described above. Lysate (750 μg) was pre-cleared with Protein A/G beads (Pierce) and mixed with a mouse monoclonal antiSmad3 antibody (4D5, used at 1:100; Abnova) or 3 μg of a rabbit polyclonal anti-S100A4 antibody (Dako Cytomation) and incubated at 4
• C overnight. Protein A/G beads were added and incubated for a further 2 h. The beads were washed, and eluted samples were subjected to Western blot analysis. The anti-S100A4 antibody described above was used for S100A4 detection. The mouse monoclonal antibody 4D5 was used to detect Smad3 following the precipitation by the anti-S100A4 antibody, whereas a rabbit monoclonal anti-Smad3 antibody (C67H9; Cell Signaling) was used for the detection of precipitated protein by 4D5.
BIAcore interaction analysis
A BIAcore assay was carried out following the manufacturer's instructions (Biosensor). His-S100A4 (17.5 ng ≈ 1.75 pmol) was immobilized on a BIAcore Sensor Chip CM5 using an amine coupling kit. The chip was equilibrated with running buffer [50 mM Hepes (pH 7.2) and 100 mM NaCl] either in the presence of Ca 2+ (1 mM CaCl 2 ) or its absence (1 mM EGTA). An appropriate amount of GST proteins in 40 μl were injected into the BIAcore instrument. Sensorgrams (time against relative resonance units, where 1 resonance unit is equivalent to l pg of protein/mm 2 on the sensor surface) were recorded and analysed using the accompanying software, BIAevaluation. For calculation of kinetic parameters, sensorgrams using a BSA-coated chip were subtracted from those using His-S100A4.
Mammalian two-hybrid assay and Smad-responsive reporter assay
For the mammalian two-hybrid assay, HEK-293T cells on a 12-well plate were transfected with pRLTK (2 ng), HA-TβRI (12.5 ng), GAL4-Luc (100 ng) and GAL4-Smad3 (80 ng), along with 80 ng of pFN10A vector, VP16-S100A4 or VP16-c-Jun. The barnase fragment had been deleted from the pFN10A vector because of its toxicity. At 24 h post-transfection, cells were treated or left untreated with 500 pM TGF-β for 20 h and subjected to a luciferase assay using the dual reporter assay system (Promega). The Smad-responsive reporter gene assay has been described previously [29] . (A) Smad3 and Smad2 bind to S100A4 in a Ca 2+ -dependent manner in a GST-pulldown assay. HEK-293T cells were transfected with 6 × Myc-tagged Smad2, Smad3 or 3 × FLAG-tagged p53. The cell lysate was subject to a GST-pulldown assay with GST-S100A4, or GST as a control. EGTA or CaCl 2 to 1 mM was included throughout the procedure. Smad proteins and p53 recovered on the beads were detected by Western blot analysis with anti-Myc (left-hand panel) and anti-FLAG (middle panel) antibodies respectively. For input lanes, 2 % of the lysate used for the precipitation was applied. Right-hand panel: the amounts and purity of GST and GST-S100A4 on the beads were examined. The molecular mass in kDa is indicated on the right-hand side of the gel. (B) Smad3 and S100A4 interact at the endogenous protein level. Cell lysates of MDA-MB-231 cells (with or without TGF-β treatment) were immunoprecipitated (IP) with an anti-Smad3 antibody (left-hand panel) or anti-S100A4 antibody (right-hand panel). Precipitated proteins were detected by Western blot analysis (WB). Control IgG was used as a negative control (con). CaCl 2 was included at 1 mM throughout the procedure in all samples except for the EGTA sample. Co-IP, co-immunoprecipitation. (C) Smad3 binds to S100A4 in a BIAcore assay. His-S100A4 was immobilized on the BIAcore sensor chip. The same amount of GST or GST-Smad3 (40 μl of 174 nM) was applied to the BIAcore instrument with buffer containing 1 mM CaCl 2 . Sensorgrams are shown for GST and GST-Smad3. The curve of GST returns to baseline (no binding), whereas that of GST-Smad3 stays above the baseline (binding). (D) Smad3 binds to S100A4 in a Ca 2+ -sensitive manner in a BIAcore assay. GST-Smad3 binding to immobilized S100A4 was examined with buffer containing 1 mM CaCl 2 or 1 mM EGTA. RU, resonance units.
RT (reverse transcription)-qPCR (quantitative PCR)
Retrovirus-infected MCF10CA1a.cl1 cells in low-serum medium (1 % horse serum) were treated with 500 pM TGF-β or left untreated for 7 h. Total RNA was prepared and primary cDNA was synthesized using the high-capacity RT kit from Applied Biosystems. qPCR was carried out using the Taqman gene expression assays kit (Applied Biosystems) with the ABIPrism 7700 system. β-Actin was used as an internal reference. For MDA-MB 231 cells, siRNA-transfected cells were subjected to the procedure above, except that TGF-β treatment was for 8 h.
MMP-9 zymography and Western blot analysis of conditioned medium
Retrovirus-infected MCF10CA1a.cl1 cells or siRNA-transfected MDA-MB 231 cells in 60 mm plates were treated with TGF-β in 2 ml of low-serum medium for 24 h. Non-reducing SDS sample buffer was added to the conditioned medium. After a 10 min incubation at room temperature (25 • C), an appropriate amount of the sample was separated by SDS/PAGE (7.5 % gels containing 1 mg/ml gelatin). The gel was washed for 20 min (or longer) successively with Buffer 1 (3 mM sodium azide and 2.5 % Triton X-100), Buffer 2 [3 mM sodium azide, 2.5 % Triton X-100 and 50 mM Tris/HCl (pH 7.5)], Buffer 3 [3 mM sodium azide, 2.5 % Triton X-100, 50 mM Tris/HCl (pH 7.5), 5 mM CaCl 2 and 1 μM ZnCl 2 ] and Buffer 4 [3 mM sodium azide and 50 mM Tris/HCl (pH 7.5)]. The gel was then incubated in fresh Buffer 4 for 5-6 h at 37
• C. The gel was Coomassie-Blue-stained for negative-stained bands that represent MMP-9 activity.
For MMP-9 Western blot analysis, conditioned medium was concentrated 10-fold and SDS sample buffer was added to 1 × (reducing buffer). The sample was subjected to Western blot analysis for MMP-9 protein.
Cell invasion assay
Retrovirus-infected MCF10CA1a.cl1 cells were treated or left untreated with 500 pM TGF-β for 24 h in DMEM/F12 containing 1 % horse serum. The cells were trypsinized and resuspended in DMEM/F12 and 0.1 % BSA at 8 × 10 5 cells/ml. TGF-β (at a concentration of 500 pM) was kept included for those cells that had been treated with the cytokine. A 250 μl aliquot of the suspension was applied into the inner chamber of a cell invasion plate assembly in a QCM 24-well cell invasion assay kit (Chemicon International). The lower chamber contained 500 μl of the medium with 5 % horse serum, with or without TGF-β. The cells were incubated at 37
• C for 30 h. Invaded cells were fluorimetrically detected according to the manufacturer's instruction.
siRNA-transfected MDA-MB-231cells were treated as described above. Cell suspension (2 × 10 5 cells/300 μl of DMEM and 0.1 % BSA with or without 500 pM TGF-β) was applied to the Millicell hanging cell culture insert (8 μm pore size, Millipore) that had been pre-coated with Matrigel TM (BD Biosciences). The inserts were placed in the 24-well plate with DMEM and 10 % FBS with or without 500 pM TGF-β, and incubated for 24 h. Unmigrated cells on the upper side were removed using a cotton swab and cells that had migrated to the other side of the membrane were stained with 0.1 % Crystal Violet, 20 % ethanol and 1 % formaldehyde. The number of migrated cells was counted for quantification. 
RESULTS AND DISCUSSION
Smad3 and Smad2 can physically interact with S100A4
A possible explanation for the conflicting dual role of TGF-β signalling in cancer progression is that the signal transduction pathway functionally has two arms (tumour suppressive and promoting) [6] . In normal cells, the tumour-suppressive arm dominates the other so the net response is growth inhibition. In advanced cancer cells, the components for the tumour-suppressive arm are selectively inactivated, so the tumour-promoting arm can take the advantage [6] . However, the components in the tumourpromoting arm equipped in normal cells may not be sufficient to drive cancer cells into full malignancy. From this idea, we hypothesized that cancer cells may utilize additional components whose expression is elevated in cancer cells to modulate the TGF-β signal for more aggressive behaviour.
MAPKs (mitogen-activated protein kinases) and Akt, which are highly activated in cancer cells, together with TGF-β mediate the EMT (epithelial-mesenchymal transition), a prerequisite step for the rest of the metastatic behaviour of cells [11, 12, 33] . In cancer cells, the canonical TGF-β/Smad pathway also mediates pro-metastatic signals [34] [35] [36] . On the basis of the hypothesis above, we sought proteins that are highly expressed in tumours and could interact with Smad protein(s). One of the candidates for such proteins is S100A4, a member of a large family of Ca 2+ -binding proteins (the S100 family). Interestingly, Smads have been reported to interact with calmodulin, another type of Ca 2+ -binding protein [37, 38] . Since some Ca 2+ -binding proteins can share a similar binding target motif [39, 40] , we tested whether Smad proteins and S100A4 could physically interact.
The left-hand panel of Figure 1 (A) shows a result from a GSTpulldown assay. Myc-tagged Smad2 or Smad3 was expressed in HEK-293T cells and precipitated by GST-S100A4-bound beads ( Figure 1A , right-hand panel). When CaCl 2 was included in the buffer, these proteins were recovered on the beads. However, when Ca 2+ was depleted (using EGTA), this binding was abolished. Beads with GST alone ( Figure 1A , right-hand panel) failed to precipitate Smad proteins, even in the presence of CaCl 2 , indicating that the binding is mediated by S100A4. In this assay, TGF-β treatment of cells did not significantly affect the interaction. One of the known targets of S100A4 is p53 [25] . Thus FLAG-tagged p53 was included in the assay as a positive control ( Figure 1A, middle panel) . Like Smads, p53 had Ca 2+ -dependent binding to GST-S100A4, and the assay result was similar to those with Smads overall.
Because of the low-affinity nature of the interaction (see below and [41] ), immunoprecipitation by the Smad3 antibody from MDA-MB-231 cells yielded a low amount of endogenous S100A4 ( Figure 1B, left-hand panel) . However, the coimmunoprecipitation of S100A4 is specific to the Smad3 antibody, as control IgG failed to precipitate the protein. Moreover, the co-immunoprecipitation of S100A4 by the Smad3 antibody is also Ca 2+ -dependent, consistent with the GST-pulldown assay ( Figure 1A) . Similar results were obtained in the reciprocal coimmunoprecipitation by the S100A4 antibody ( Figure 1B , righthand panel).
To analyse in vitro Smad3-S100A4 binding in more detail, we performed a BIAcore assay, which can measure low-affinity interactions more quantitatively. His-S100A4 was immobilized on a biosensor chip and GST proteins were applied to the system ( Figure 1C ). Although GST protein did not show binding to the immobilized S100A4, GST-Smad3 showed relatively weak, but nonetheless significant, binding. In the BIAcore assay, the binding was also Ca 2+ -dependent ( Figure 1D 21 μM) . The submicromolar range of K d explained the relatively low recovery in the GST-pulldown assay and coimmunoprecipitation assay; but these assays and the BIAcore assay together established the in vitro interaction between Smad3 and S100A4.
Smad3 can interact with S100A4 in the cell
We next examined, using a mammalian two-hybrid assay, whether Smad3 and S100A4 could interact in the cell (Figure 2 ). GAL4-Smad3 was co-transfected with VP16, VP16-S100A4 or VP16-cJun along with a GAL4-Luc construct. The luciferase activity was significantly higher with VP16-S100A4 than with VP16 alone, both in the absence and in the presence of TGF-β. We included c-Jun as it had been reported to interact with Smad3 using the same type of assay [42] . VP16-c-Jun showed a similar result to that of VP16-S100A4, except that the interaction seemed stronger. For both proteins, binding was increased by TGF-β treatment. This suggested that, like c-Jun [43] , the S100A4 interaction with Smad3 might be regulated by TGF-β in the cell.
S100A4 binds to the N-terminal region of Smad3
There are two calmodulin-binding sites in Smad2 and they are located in its N-terminal domain (MH-1 domain) [37, 38] . When the entire MH-1 domain was deleted from GST-Smad3 ( 142; Figure 3A ), the binding was abolished ( Figure 3B ). This result indicated that the S100A4-binding site(s) in Smad3 was also in its MH-1 domain. In Smad2, one calmodulin-binding site is at its N-terminus and the other is located in amino acids 117-124 (equivalent to amino acids 86-93 of Smad3) [38] . On the basis of this information, we deleted the first nine and 93 amino acids of GST-Smad3 ( 9 and 93; Figure 3A) . Deletion of the N-terminal nine amino acids impaired the binding, but significant binding still remained ( Figure 3B ). Further deletion to 93 amino acids almost abolished the binding ( Figure 3B ). This result suggested that the S100A4-binding region in Smad3 might overlap with that for calmodulin [38] . Consistent with this, the MH-1 domain alone (δLC) bound to S100A4. The binding of Smad3δLC is even stronger than that of the parental protein ( Figure 3B ), suggesting that another region of Smad3 may be inhibitory to the binding. Interestingly, Thr 8 , a threonine residue in the region, is a phosphorylation site for CDKs (cyclindependent kinases) and MAPKs [29, 44, 45] . We are currently investigating whether the phosphorylation of Thr 8 has any role in the interaction.
S100A4 can increase Smad transcriptional activity
The physical interaction between Smad3 and S100A4 suggested its functional and physiological significance. To evaluate the effect of S100A4 on Smad function, we performed a reporter assay with two luciferase constructs with a Smad-responsive promoter, synthetic 4 × SBE-Luc and A3-Luc/FAST-1 [44] . 4 × SBE-Luc was combined with Smad3, and A3-Luc/FAST-1 combined with Smad2. In both cases, inclusion of S100A4 significantly increased luciferase expression compared with the control (Figure 4 ). This result suggested that S100A4 could potentially increase Smad transcriptional activity.
S100A4 co-operates with the TGF-β signal for MMP-9 expression
In advanced cancer cells, Smad2 and Smad3 function as prometastatic factors [35] . From the results described above, we hypothesized that the S100A4-Smad interaction in cancer cells might stimulate the pro-metastatic potential of the Smads. MMP-9 plays important roles in metastasis and the TGF-β/Smad pathway regulates its expression [9, 15] . On the basis of this hypothesis, we tested the effect of S100A4 on MMP-9 expression. MCF10CA1a.cl1 is a highgrade carcinoma cell line derived from a MCF10A1 breast epithelial cell line [30] . The contribution of the TGF-β/ Smad2/3 pathway to the metastatic ability of this cell line has been demonstrated [31, 34] . Moreover, levels of S100A4 are low in this cell line ( Figure 5A , vector lane). From these aspects, this cell line was ideal for examining the effect of S100A4 on the TGF-β/Smad-mediated metastatic response by exogenously expressing the protein. Figure 5(A) shows the expression of S100A4 in MCF10CA1a.cl1 cells retrovirally transduced with vector or the S100A4 expression construct. The level of expression was comparable with that of MDA-MB 231 cells, a highly metastatic cell line that overexpresses S100A4 (results not shown).
The cells were treated with TGF-β and levels of MMP-9 mRNA were quantified by RT-qPCR ( Figure 5B ). MMP-9 mRNA was up-regulated by TGF-β treatment. S100A4 itself does not significantly increase the mRNA level. However, when S100A4-expressing cells were treated with TGF-β, the mRNA level was ∼ 3-fold higher than that of controls. Consistently, zymography and Western blot analysis also showed a much higher level of secreted MMP-9 from TGF-β-treated S100A4-expressing cells ( Figure 5C ). These results suggested a positive effect of the Smad-S100A4 interaction on MMP-9 gene expression. Cip1 (p21) is another TGF-β-responsive gene. However, in the MCF10CA1a.cl1 cell line, this gene does not respond to TGF-β. In this circumstance (i.e. when a gene had lost TGF-β responsiveness), S100A4 had no effect ( Figure 5D ). To further strengthen the observations above, we depleted endogenous S100A4 from MDA-MB231 cells by siRNA ( Figure 5E ). Control and S100A4-depleted cells were treated with TGF-β, and MMP-9 levels were measured by RT-qPCR, zymography and Western blot analysis (Figures 5F and 5G) . The results showed that when S100A4 is knocked down, induction of MMP-9 mRNA, activity and protein by TGF-β was greatly attenuated. MDA-MB231 cells were transfected with either control or S100A4 siRNA. Endogenous S100A4 (upper panel) and actin (lower panel) levels were examined by Western blot analysis. (F) TGF-β-induced MMP-9 gene up-regulation is compromised in S100A4-depleted MDA-MB231 cells. siRNA-transfected cells were cultured in low serum medium (1 % FBS) for 15 h. Cells were then treated or not with 500 pM TGF-β for 8 h. Total RNA was prepared and subjected to qPCR for the MMP-9 gene. Values are means + − S.D. for four independent experiments. (G) TGF-β-induced MMP-9 activity/protein is reduced in S100A4-depleted MDA-MB231 cells. siRNA-transfected cells were cultured in medium with 1 % FBS overnight before being treated or not with TGF-β for 24 h. Conditioned medium was applied to gelatin-containing polyacrylamide gels and separated by SDS/PAGE under non-reducing conditions. MMP-9 activity in the medium was detected by negative Coomassie-Blue-staining (upper panel). MMP-9 protein was detected by Western blot analysis (lower panel)
Taken together, these results suggested the involvement of S100A4 in TGF-β-stimulated MMP-9 regulation.
S100A4 can increase TGF-β-stimulated cell invasion
From the effect of S100A4 on MMP-9 up-regulation by TGF-β, we anticipated that S100A4 could have an influence on the TGF-β-stimulated invasion ability of the cancer cells. To quantitatively analyse the invasion ability, we performed an in vitro invasion assay ( Figure 6A) . Invasion of MCF10CA1a.cl1 cells with the control vector was stimulated by TGF-β treatment. This stimulation is mediated by the Smad pathway [34] . S100A4-overexpressing cells showed a higher invasion ability compared with the controls. When S100A4-overexpressing cells were treated with TGF-β, invasion was potentiated to a level much higher than either of S100A4-overexpressing cells alone or controls.
We also examined the effect of S100A4 depletion on TGF-β-stimulated cell invasion in MDA-MB-231 cells. This cell line shows strong induction of invasion by TGF-β. In this assay, we stained invaded cells for visualization ( Figure 6B , lefthand panel). As anticipated, depletion of S100A4 resulted in attenuation of the invasion ability of the cells ( Figure 6B ). This result suggested that S100A4, through an interaction with Smad proteins, could synergistically increase the cancer cell invasion.
In the present study, we have demonstrated a physical interaction of the two proteins in four different systems (Figures 1 and 2) . The affinity of the binding was relatively low (K d ∼ 0.21 μM). A low affinity to non-muscle myosin, another target of S100A4, has been reported [41] . In a situation where S100A4 is highly overexpressed (i.e. in some cancer cells), considerable interaction between S100A4 and the target proteins would still occur, even with the low affinity. Moreover, a higher Ca 2+ level has been noted due to an alteration of Ca
2+
homoeostasis in cancer cells [46] . Consistent with this notion, their interaction in the cell was detected in a mammalian twohybrid assay, where S100A4 was exogenously overexpressed (Figure 2 ). Importantly, the expression level of endogenous S100A4 in the MDA-MB 231 breast cancer cell line can be comparable with that of the exogenous protein (results not shown). Thus this interaction would occur in cancer cells overexpressing S100A4.
In conclusion, we have provided a possible mechanism of how TGF-β and Smad proteins become stronger metastatic-promoting factors in some advanced tumours. Overexpression of S100A4 in cancer cell lines strongly correlates with p53 status (deletion or mutation) [25] . Although the detailed mechanism is unknown, this strongly suggests that wild-type p53 keeps cells from overexpressing S100A4. A p53 mutation may actively co-operate with the TGF-β signal for a more aggressive behaviour of cancer cells. Recently, Adorno et al. [43] have reported that the p53 mutant observed in many types of cancer enpowers TGF-β-induced metastasis through the Smad pathway. Their observations and the results of our present study suggest that p53 status may be a key to TGF-β-mediated malignancy, and influences pro-metastatic activity of TGF-β at multiple levels. A p53 mutant, through direct interaction with Smads, on one hand down-regulates metastasis inhibitory genes such as Sharp-1 and Cyclin G2 [43] ; on the other hand it turns on S100A4 expression to increase TGF-β/Smadmediated cell invasion ability.
It is possible that, in addition to S100A4, some other proteins overexpressed in cancer cells may also modulate Smad function. Finding such additional Smad partners in cancer will establish a model in which TGF-β/Smad signalling promotes the progression of advanced tumours and may provide important therapeutic implications.
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